Breaking News

Recro Pharma Awarded NIH Development, Mfg. Contract

Will support Chemistry, Manufacturing and Controls (CMC) development of NES-100, a novel nasal spray analgesic.

Author Image

By: Charlie Sternberg

Associate Editor

Recro Pharma Inc., a contract development and manufacturing organization (CDMO) dedicated to solving formulation and manufacturing challenges, has been awarded a new development and manufacturing contract by the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH).   The contract, “Dosage Form Development, Manufacture, and Stability Studies of NES-100 Nasal Spray,” focuses on NES-100, a novel nasal spray analgesic.     About the Contract ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters